Keytruda Now FDA-Approved for Patients with Melanoma
The KEYNOTE-054 Phase 3 clinical trial (NCT02362594) showed that the immune checkpoint inhibitor drug Keytruda decreased the risk of melanoma recurrence or death by 43% in comparison to a placebo drug. The drug has thus been approved by the U.S. Food and Drug Administration (FDA) to treat patients with stage-3 melanoma (cancer has spread to […]
Continue readingNISC-6 Shows Potential Against Skin Cancer
What is NISC-6? Based on a recent study, a new compound found in cruciferous vegetables has been identified to act as the base for a new drug that has the potential to kill melanoma in the skin without affecting healthy cells. Two researchers from Penn State College of Medicine designed a compound called NISC-6 […]
Continue readingDisrupting Melanoma Defense Mechanism
Melanoma is a very aggressive type of skin cancer that develops from melanocytes – the skin’s pigment-producing cells. Although uncommon, melanoma has the highest mortality rate and the highest potential to spread out of all skin cancers, which verifies that it can be fatal. Since it is particularly tough to treat when it mutates, melanoma […]
Continue reading